StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.89+0.22 (+1.61%)

Close on Nov 18, 2026Market cap $340.38MP/E –Yield –

Lyell Immunopharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Lyell Immunopharma's revenue for the twelve months ending Jun 30, 2026 was $27.00K, down 55.0% year over year. For fiscal 2025 it was $36.00K, down 41.0% from the year before. The highest annual figure on record is $84.68M in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$36.00K-41.0%
FY2024Dec 31, 2024$61.00K-53.1%
FY2023Dec 31, 2023$130.00K-99.8%
FY2022Dec 31, 2022$84.68M+695.1%
FY2021Dec 31, 2021$10.65M+37.3%
FY2020Dec 31, 2020$7.76M+1080.5%
FY2019Dec 31, 2019$657.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.00K-50.0%
Q1 FY2026Mar 31, 2026$2.00K-71.4%
Q4 FY2025Dec 31, 2025$6.00K-45.5%
Q3 FY2025Sep 30, 2025$15.00K-55.9%
Q2 FY2025Jun 30, 2025$8.00K-38.5%
Q1 FY2025Mar 31, 2025$7.00K+133.3%
Q4 FY2024Dec 31, 2024$11.00K-15.4%
Q3 FY2024Sep 30, 2024$34.00K+36.0%
Q2 FY2024Jun 30, 2024$13.00K-51.9%
Q1 FY2024Mar 31, 2024$3.00K-95.4%
Q4 FY2023Dec 31, 2023$13.00K-100.0%
Q3 FY2023Sep 30, 2023$25.00K+733.3%
Q2 FY2023Jun 30, 2023$27.00K-99.9%
Q1 FY2023Mar 31, 2023$65.00K-88.2%
Q4 FY2022Dec 31, 2022$48.39M+1614.6%
Q3 FY2022Sep 30, 2022$3.00K-99.9%
Q2 FY2022Jun 30, 2022$35.74M+1260.0%
Q1 FY2022Mar 31, 2022$553.00K-77.4%
Q4 FY2021Dec 31, 2021$2.82M+22.1%
Q3 FY2021Sep 30, 2021$2.76M+157.5%
Q2 FY2021Jun 30, 2021$2.63M-15.7%
Q1 FY2021Mar 31, 2021$2.45M–
Q4 FY2020Dec 31, 2020$2.31M–
Q3 FY2020Sep 30, 2020$1.07M–
Q2 FY2020Jun 30, 2020$3.12M–

More Lyell Immunopharma figures

See a number that looks wrong?